A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

Inclusion Criteria: * Male or female between the ages of 18 and 70 years, inclusive at the screening visit. * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * BMI of 17.5 to 38.0 kg/m2, inclusive, and a total body weight \>50 kg (110 lb). * Group 1 only: at screening, no clinically relevant abnormalities identified by a detailed medical history, physical exam, including blood pressure and pulse rate measurement, ECG and clinical laboratory tests. * Group 1 only: no known or suspected hepatic impairment and meet the criteria based on screening laboratory liver function tests. * Groups 2, 3 \& 4 only: stable hepatic impairment that meets criteria for Class A, B, or C of the Child-Pugh classification with no clinically significant change in disease status within 28 days before screening. * Groups 2, 3 \& 4 only: stable concomitant medications for the management of individual participant's medical history. Exclusion Criteria: * Any condition possibly affecting drug absorption * At screening, a positive result for HIV antibodies. * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or participants with suspected MTC per study doctor's judgement. * History of acute pancreatitis within 6 months before the screening visit or any history of chronic pancreatitis. * Other medical or psychiatric condition or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study. * Use of specific prohibited prior/concomitant therapies * Use of an investigational product within 30 days (or local requirement) or 5 half-lives (whichever longer). * eGFR\<60 mL/min/1.73m2 at screening. * A positive urine drug test at screening or admission to study clinic. * At screening or admission to study clinic, a positive breath alcohol test. * For females, pregnancy, as indicated by a positive serum pregnancy test at screening and/or positive urine pregnancy test in women capable of having children at admission to study clinic * Group 1 only: evidence of chronic liver disease including history of hepatitis, hepatitis B, or hepatitis C. * Group 1 only: history of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of screening. * Group 1 only: screening ECG demonstrating QTcF interval \>450 ms or a QRS interval \>120 ms. * Group 1 only: screening seated systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg * Group 1 only: use of chronic prescription medications within 7 days or 5 half-lives (whichever longer) before Day 1, or for prohibited medications, use within the required washout/restriction period. * Group 2, 3 \& 4 only: Hepatic carcinoma or hepatorenal syndrome or limited predicted life expectancy (defined as \<1 year in Groups 2 \& 3 and \<6 months for Group 4 only). * Group 2, 3 \& 4 only: a diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular process that is documented by medical history, physical exam, liver biopsy, hepatic ultrasound, CT scan, or MRI. * Group 2, 3 \& 4 only: history of surgery that would be expected to alter absorption, distribution, metabolism, or excretion properties of PF-07081532. * Group 2, 3 \& 4 only: history of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 4 weeks prior to screening. * Group 2, 3 \& 4 only: signs of clinically active Grade 3 or 4 hepatic encephalopathy * Groups 2, 3 \& 4 only: severe ascites and/or pleural effusion, except for those categorized in Group 4 who may be enrolled provided participant is medically stable, per the study doctor's judgment. * Groups 2, 3 \& 4 only: previously received a kidney, liver, or heart transplant. * Groups 2, 3, \& 4 only: screening ECG demonstrating a QTcF interval \>470 ms or a QRS interval \>120 ms. * Groups 2, 3 \& 4 only: at screening, admission to study clinic or pre-dose on Day 1, persistent severe, uncontrolled hypertension. * Groups 2, 3 \& 4 only: ALT or AST \>5x upper limit of normal on clinical laboratory tests at screening.